These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7765373)

  • 1. Production and characterization of a novel tissue-type plasminogen activator derivative in Escherichia coli.
    Saito Y; Ishii Y; Sasaki H; Hayashi M; Fujimura T; Imai Y; Nakamura S; Suzuki S; Notani J; Asada T
    Biotechnol Prog; 1994; 10(5):472-9. PubMed ID: 7765373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Lill H; Rudolph R; Sponer G; Stern A; Strein K
    Z Kardiol; 1990; 79 Suppl 3():167-70. PubMed ID: 2129142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
    Ikenaka Y; Yajima K; Yahara H; Maruyama H; Matsumoto K; Okada K; Ueshima S; Matsuo O
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
    Hunt JA; Petteway SR; Scuderi P; Novokhatny V
    Thromb Haemost; 2008 Sep; 100(3):413-9. PubMed ID: 18766256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The production of improved tissue-type plasminogen activator in Escherichia coli.
    Mattes R
    Semin Thromb Hemost; 2001 Aug; 27(4):325-36. PubMed ID: 11547355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
    J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.
    Wilhelm OG; Jaskunas SR; Vlahos CJ; Bang NU
    J Biol Chem; 1990 Aug; 265(24):14606-11. PubMed ID: 2117612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
    de Vries C; Veerman H; Nesheim ME; Pannekoek H
    Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and function of human tissue-type plasminogen activator (t-PA).
    van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
    J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism between tissue-type plasminogen activator and a genetically engineered variant lacking the finger domain, the growth factor domain and the first kringle domain.
    Mattson C; Wikström K; Sterky C; Pohl G
    Thromb Haemost; 1991 Mar; 65(3):286-90. PubMed ID: 1710837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
    Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
    J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of aspartic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis.
    Weening-Verhoeff EJ; Quax PH; van Leeuwen RT; Rehberg EF; Marotti KR; Verheijen JH
    Protein Eng; 1990 Dec; 4(2):191-8. PubMed ID: 1963688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain.
    Burck PJ; Berg DH; Warrick MW; Berg DT; Walls JD; Jaskunas SR; Crisel RM; Weigel B; Vlahos CJ; McClure DB
    J Biol Chem; 1990 Mar; 265(9):5170-7. PubMed ID: 2108167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular biology of tissue-type plasminogen activator (t-PA) and clinical application of recombinant t-PA].
    Fukao H; Matsuo O
    Nihon Rinsho; 1993 Jun; 51(6):1620-6. PubMed ID: 8320841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.